Apogee Therapeutics (APGE) Income towards Parent Company (2022 - 2026)

Apogee Therapeutics (APGE) has 5 years of Income towards Parent Company data on file, last reported at -$74.1 million in Q1 2026.

• On a quarterly basis, Income towards Parent Company fell 33.92% year-over-year to -$74.1 million in Q1 2026; TTM through Mar 2026 was -$220.7 million, a 7.73% decrease from a year earlier, with the FY2025 full-year figure at -$201.9 million, down 11.18% from the prior year.
• Income towards Parent Company for Q1 2026 stood at -$74.1 million, down from -$15.4 million in the prior quarter.
• Over the last five years, Income towards Parent Company for APGE reached as high as -$1.8 million in Q2 2022 and fell as low as -$74.1 million in Q1 2026.
• Historically, Income towards Parent Company has averaged -$37.9 million across 5 years, with a median of -$33.0 million in 2024.
• Across the five-year window, Income towards Parent Company slumped 939.92% in 2023 and surged 76.84% in 2025, its largest moves.
• Year by year, Income towards Parent Company stood at -$20.8 million in 2022, then sank by 197.92% to -$61.9 million in 2023, then dropped by 7.66% to -$66.7 million in 2024, then jumped by 76.84% to -$15.4 million in 2025, then plunged by 379.99% to -$74.1 million in 2026.
• Per Business Quant data, the three most recent Income towards Parent Company figures were -$74.1 million in Q1 2026, -$15.4 million in Q4 2025, and -$65.0 million in Q3 2025.